Bcrf1 proteins as inhibitors of interferon-y
CA 2071907 C · Owner: Schering Corporation · Inventors: Moore, Kevin W.; Kastelein, Robert
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
BCRF1 proteins, and expression vectors for producing them are provided for , treating conditions associated with excessive production of IFN-.gamma.. Compositions of the invention containing BCRF1 proteins are useful in treating a variety of disorders including allergy, psoriasis, tissue rejection and MHC-linked autoimmune , diseases.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 18, 1990 and granted August 8, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 18, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 18, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.